361 Capital’s Halozyme HALO Stock Holding History

361 Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$1.08M	Sell	40,453 -6,279	-13%	-$142K	0.51%	27
2020 Q1	$841K	Sell	46,732 -30,088	-39%	-$571K	0.38%	85
2019 Q4	$1.36M	Sell	76,820 -85,238	-53%	-$1.48M	0.38%	105
2019 Q3	$2.51M	Sell	162,058 -3,689	-2%	-$60.8K	0.46%	90
2019 Q2	$2.85M	Sell	165,747 -11,727	-7%	-$189K	0.51%	50
2019 Q1	$2.86M	Buy	177,474 +17,601	+11%	+$285K	0.5%	71
2018 Q4	$2.34M	Buy	+159,873	New	+$2.55M	0.48%	78
2018 Q1	–	Sell	-68,250	Closed	-$1.38M	–	300
2017 Q4	$1.38M	Buy	68,250 +56,343	+473%	+$1.04M	0.34%	157
2017 Q3	$207K	Buy	+11,907	New	+$161K	0.04%	239

Other funds holding HALO

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

361 Capital's HALO Position: Q2 2020 in Review

361 Capital reduced its Halozyme (HALO) stake by 13% in Q2 2020, selling an estimated $142K and leaving 40,453 shares worth $1.08M. The position accounts for 0.51% of the portfolio, ranked #27.

361 Capital first reported a position in HALO in Q3 2017 and has held it in 9 quarters since. The position peaked at $2.86M in Q1 2019. 264 funds tracked by Wall St. Rank hold HALO as of Q2 2020.

361 Capital held 40,453 shares of Halozyme worth $1.08M as of Q2 2020.
361 Capital sold 6,279 Halozyme shares in Q2 2020, an estimated $142K.
Halozyme made up 0.51% of 361 Capital's portfolio in Q2 2020, its #27 holding.
361 Capital first reported a position in Halozyme in Q3 2017 and has held it in 9 quarters since.
361 Capital's Halozyme position peaked at $2.86M in Q1 2019.
264 funds tracked by Wall St. Rank held Halozyme as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.